Upsher-Smith Labs launches topical medication for skin itching and inflammation

MAPLE GROVE, Minn. — Upsher-Smith Labs has launched a topical medication for itching and inflammation of the skin resulting from such conditions as psoriasis and atopic dermatitis, the company said Monday.

Upsher-Smith announced the launch of Trianex (triamcinolone acetonide) ointment, which the company described as a prescription topical corticosteroid that offers the feel of a cream and the strength of an ointment.

“With Trianex, physicians and patients have the best of both worlds: a mid-potency treatment option that delivers the strength of an ointment in a proprietary cream-like base that may be pleasing to patients,” Upsher-Smith director for product marketing Glenn MacEachern stated. “The base for topical corticosteroids is one of many factors that may affect patient compliance, and we are pleased to offer Trianex as a unique option for sufferers of inflammation and itching due to corticosteroid-responsive skin conditions.”